Beyond Medical Frontiers – AstraZeneca’s Innovative Medicines

AstraZeneca is a global biopharmaceutical company, which develops and manufactures widely-used medications based on scientific research in various therapeutic areas. The company distributes and commercializes medications worldwide.

The representation of AstraZeneca in Georgia was established in 2009. It currently offers 18 different drugs on the local market. The company ensures the provision of information continuously to specialists about the latest scientific achievements and findings in compliance with the highest ethical standards.

Corporate sustainability is a part of the company’s strategy. AstraZeneca takes care of access to healthcare, environment protection and transparency.            

Globally, the company concentrates its efforts on three major therapeutic areas providing a significant relief to patients in the treatment process: oncology, cardiovascular and metabolic diseases; respiratory system, inflammatory and autoimmune rare diseases.

Over these years the Georgia office has implemented a number of patient-oriented projects in the context of diagnostics and accessibility. The company also has greatly contributed tthe continuous medical education of healthcare specialists.

The most important diagnostic project – introduction and implementation of EGFR testing was for lung cancer patients in Georgia, in the form of support to patients’ organization – in particular projects implemented jointly with Europa Donna: from donation of medical products to a psychotherapy course. Worth mentioning is the company’s support to patients with rare diseases.  – the company has made a real progress in this area – iInnovative preparations have been created for seven rare inherited disorders with five of them authorized. Hypophosphatasia –  a genetic, chronic, progressive and life-threatening metabolic condition is one of the disorders. The Representative Office of AstraZeneca cooperated with doctors from Iashvili Clinic to help a 7-year-old patient with hypophosphatasia. With global access to medications program all clinical criteria were met and a complete treatment course with the innovative preparation STRENSIQ was fully financed for the patient. Treatment of the patient is still ongoing. It should be mentioned that the drug demonstrated high efficiency and safety.

AstraZeneca Georgia, as a company with high corporate responsibility, does not only create high-quality medications for patients but also cares for the environment and sustainable development as well. As part of the company’s Green Initiative, the company planted saplings at a number of public places. In October this year, with support from Rustavi City Hall, AstraZeneca selected and purchased 20 saplings appropriate for the local climate for a Rustavi kindergarten.

AstraZeneca joined the 0% carbon campaign of Georgia. The company vehicle fleet has been 100% green since 2022 (only hybrid models). Transferring to fully electric models is planned by the end of 2025.

AstraZeneca’s corporate responsibility was high during the pandemic as well. Globally, it was the company’s initiative to promote vaccine production and increasing its accessibility without commercialization. AstraZeneca was the first company to join the COVAX platform. Georgia was among the first countries to receive the vaccine from COVAX; the company gave over 5000 medical masks to the National Center for Disease Control and Public Health.

During the pandemic the representative office of AstraZeneca did everything to prevent delays in continuous supply of vital medications by the company. This was carried out while maintaining the safety of its employees. Official meetings were quickly and efficiently transferred to a remote mode.

The company’s representative office in Georgia properly maintains global norms and standards of ethical behavior effective in all the countries of operation of AstraZeneca in full compliance of ABAC Global Standard and the Code of Ethics (developed by IFPMA_US; EFPIA-UK); AstraZeneca is a member and has also joined the Code of Ethics of pharmaceutical company representatives developed in compliance with the requirements of the International Federation of Pharmaceutical Manufacturers & Associations  (IFPMA).

Georgia representative office of AstraZeneca UK Limited has developed a project called Tanadgoma for patients, which has fully launched since 2021. The project is ongoing and is aimed at supporting patients with acute and chronic diseases in such fields as cardiology, pulmonology. It is also aimed at increasing patients’ awareness of various diseases in the relevant therapeutic fields, reducing the cost of therapy by the drugs included in the Program.

Patients holding Tanadgoma cards purchase the drugs included in the program at a reduced price. The program is only intended for patients who have the drugs prescribed by a doctor.

Purchasing the drug at a reduced price within the program is possible at any pharmacy participating in the program. Additional information is provided at the official website of the project www.tanadgoma.com.ge 

The mission of AstraZeneca is to become a successful and reliable healthcare partner with the strongest portfolio of innovative medicines and to help millions of patients with the best team of professionals.

A part of the Mission of AstraZeneca Georgia is to maintain all approaches to date and implement the company’s latest achievements to the extent possible so that innovative and effective products are available for the population of Georgia.

At AstraZeneca Georgia we believe that the best way to help patients is to focus on scientific achievements to discover the yet unfamiliar mechanisms of diseases and create the latest targeted medical products. The most important goal of the company is to cross medical frontiers in order to create medications for the improvement of the quality of life.

The company is a leading and reliable healthcare partner with the strongest portfolio of innovative medicines and the best team of professionals to assist millions of patients.

The information is intended for wide audience;

Contact information: AstraZeneca UK Limited Representative Office in Georgia

Address: D. Gamrekeli #19, Tel: +995 32 23868 98